Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may predict sepsis survival in ICU

NCT ID NCT07285499

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a simple blood test score, called the CALLY index, can help predict how well adult sepsis patients will do in the intensive care unit (ICU). Researchers reviewed medical records of 276 patients to see if the CALLY index was linked to the risk of death within 30 days or kidney problems. No new treatments or procedures were given, so there was no added risk to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

276 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult ICU patients diagnosed with sepsis and treated at Ankara University Medical Faculty Hospital.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Sepsis diagnosis meeting Sepsis-3 criteria * ICU stay ≥ 5 days * Complete CRP, albumin, and lymphocyte laboratory results available for days 0, 3, and 5 Exclusion Criteria: * • Chronic Kidney Disease stage ≥3 * Liver diseases including cirrhosis, chronic hepatitis, or hepatic failure * Hematologic diseases such as leukemia, lymphoma, MDS, or multiple myeloma * Rheumatologic diseases including SLE, rheumatoid arthritis, or systemic sclerosis * Use of immunosuppressive therapy * ICU stay shorter than 5 days * COVID-19 positive status * Missing laboratory data preventing calculation of CALLY index

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ankara University Faculty of Medicine - Intensive Care Unit

    Ankara, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.